Baxter International Inc (BAX)

Currency in USD
26.16
-0.59(-2.21%)
Closed·
26.15-0.01(-0.04%)
·
BAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
26.0327.15
52 wk Range
15.7330.00
Key Statistics
Prev. Close
26.75
Open
26.92
Day's Range
26.03-27.15
52 wk Range
15.73-30
Volume
9.28M
Average Volume (3m)
6.83M
1-Year Change
19.1257%
Book Value / Share
11.7
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
BAX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
27.29
Upside
+4.33%
Members' Sentiments
Bearish
Bullish
ProTips
6 analysts have revised their earnings downwards for the upcoming period

Baxter International Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Analyst Ratings

2 Buy
12 Hold
0 Sell
Ratings:
14 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 27.29
(+4.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
TD Cowen
Hold29.00+10.86%24.00MaintainJul 31, 2026
Wells Fargo
Hold23.00-12.08%19.00MaintainJul 31, 2026
Stifel
Hold28.00+7.03%24.00MaintainJul 31, 2026
Citi
Hold28.00+7.03%17.00UpgradeJul 31, 2026
UBS
Hold25.00-4.43%19.00MaintainJul 28, 2026

Baxter International Inc SWOT Analysis


Healthcare Titan
Baxter International, a $17.85B market cap leader in medical supplies, boasts a 55-year dividend streak amid industry shifts
Analyst Optimism
Barclays reinstates Overweight rating with $39 price target, signaling renewed confidence in Baxter's market outperformance potential
Financial Resilience
EPS projections show growth from $2.50 in FY2025 to $2.28 in FY2, with analysts predicting a return to profitability despite recent challenges
Strategic Positioning
Baxter navigates regulatory hurdles and competitive pressures while capitalizing on aging populations and emerging markets for sustained growth
Read full SWOT analysis

Baxter International Inc Earnings Call Summary for Q2/2026

  • Baxter Q2 2026 EPS of $0.56 beat estimates by 51%, revenue of $2.96B topped forecasts by 5.7%; shares surged 15.79% to near 52-week highs.
  • Company raised FY2026 guidance: organic sales growth 2-3%, adjusted EPS $1.95-$2.15 (up from $1.85-$2.05), targeting 3.0x net leverage by year-end.
  • Revenue grew 5% YoY with Advanced Surgery up 12%, drug compounding double-digits; margins compressed 210bps on gross, 90bps on operating basis.
  • CEO Hider emphasized H2 2026 execution critical for 2027 path; Q2 included non-recurring $75M tariff refund adding $0.11/share to results.
  • Challenges persist: Novum IQ LVP correction ongoing, injectable supply constraints continue; expects $40M net tariff impact in second half.
Last Updated: 07/30/2026, 10:04 PM
Read Full Transcript

Earnings

Latest Release
Jul 30, 2026
EPS / Forecast
0.56 / 0.37
Revenue / Forecast
2.96B / 2.8B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS -2.06%
Dividend Yield
0.15%
Industry Median 1.53%
Annualized payout
0.04
Paid quarterly
5-Years Growth
-18.15%
Growth Streak

BAX Income Statement

Compare BAX to Peers and Sector

Metrics to compare
BAX
Peers
Sector
Relationship
P/E Ratio
−14.0x14.8x−0.3x
PEG Ratio
0.020.290.00
Price/Book
2.2x1.2x2.6x
Price / LTM Sales
1.2x0.9x3.0x
Upside (Analyst Target)
5.2%0.0%56.7%
Fair Value Upside
Unlock45.4%9.4%Unlock

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors’ offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
343.58M66.52%8.99B
Other Institutional Investors
215.04M33.48%5.63B
Public Companies & Retail Investors
0.000.00%0.00
Total
558.62M100.00%14.61B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.15.37%79,400,6642,077,121
Pzena Investment Management, Inc.12.49%64,527,8231,688,048

People Also Watch

105.56
EPAM
+1.83%
55.35
CTSH
+2.69%
72.32
COO
-0.45%
279.05
CI
-2.99%
165.35
PODD
-0.20%

FAQ

What Is the Baxter (BAX) Stock Price Today?

The Baxter stock price today is 26.16 USD.

What Stock Exchange Does Baxter Trade On?

Baxter is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Baxter?

The stock symbol for Baxter is "BAX."

Does Baxter Pay Dividends? What’s The Current Dividend Yield?

The Baxter dividend yield is 0.15%.

What Is the Baxter Market Cap?

As of today, Baxter market cap is 13.83B USD.

What Is Baxter's Earnings Per Share (TTM)?

The Baxter EPS (TTM) is -2.06.

When Is the Next Baxter Earnings Date?

Baxter will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is BAX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Baxter Stock Split?

Baxter has split 4 times.

How Many Employees Does Baxter Have?

Baxter has 37500 employees.

What is the current trading status of Baxter (BAX)?

As of Aug 01, 2026, Baxter (BAX) is trading at a price of 26.16 USD, with a previous close of 26.75 USD. The stock has fluctuated within a day range of 26.03 USD to 27.15 USD, while its 52-week range spans from 15.73 USD to 30.00 USD.

What Is Baxter (BAX) Price Target According to Analysts?

The average 12-month price target for Baxter is 27.29 USD, with a high estimate of 40 USD and a low estimate of 19 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +4.33% Upside potential.

What Is the BAX Premarket Price?

BAX's last pre-market stock price is 26.91 USD. The pre-market share volume is 18,470.00, and the stock has decreased by 0.16, or 0.60%.

What Is the BAX After Hours Price?

BAX's last after hours stock price is 26.15 USD, the stock has decreased by -0.01, or -0.04%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.